Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
According to a new paper in the journal Cell, researchers at the Sanger Institute at Cambridge, in England, believe they have discovered a completely new mechanism for the initial development of about 2 or 3 percent of all cancers.
Filed under: Diagnosis, Risk | Tagged: cause, chromosome, chromothripsis, DNA, mutation | Leave a Comment »
Apparently the German health system is to initiate a large trial to investigate the comparative effectiveness of four different treatments for men initially diagnosed with low-risk prostate cancer, starting this year.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: active surveillance, brachytherapy, comparative effectiveness, external beam radiation therapy, German, radical prostatectomy | Leave a Comment »
A new article in Radiation Oncology provides initial 5-year outcomes of patients treated with stereotactic body radiation therapy (SBRT), also known as CyberKnife therapy.
Filed under: Management, Treatment, Uncategorized | Tagged: CyberKnife, outcome, SBRT, sterotactic body radiation therapy | 2 Comments »
Over the past 5 or so years we have seen a remarkable growth in the diversity of pharmaceuticals being developed for the treatment of more advanced forms of prostate cancer, and there is no sign of a slow-down yet.
Filed under: Drugs in development | Tagged: androgen receptor, EZN-4176, mRNA antagonist | Leave a Comment »
In recent years, it has become increasingly well understood that patients diagnosed with low-risk prostate cancer are potentially susceptible to over-treatment. This is particularly the case among men who have significant degrees of co-morbidity and men greater than 75 years of age who have a life expectancy of < 15 years.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Charlson score, Co-morbidity, low risk, over-treatment, risk | Leave a Comment »
A study by researchers at the University of Miami and Yale School of Medicine suggests there may be an association between patients’ beliefs about the potential curability of prostate cancer and their overall, long-term survival.
Filed under: Living with Prostate Cancer | Tagged: belief, outcome, survival | 8 Comments »
Back in the mid-1990s there was 3D-CRT (three-dimensional conformal beam radiation therapy), the first type of external beam radiation designed to “shape” the way that beams of radiation were used to treat the prostate in conformance with the actual shape of the individual prostate.
Filed under: Management, Treatment | Tagged: IMPT, ProBeam, proton beam radiation therapy, Varian | 1 Comment »
Over the years a number of studies have documented a reduction in penile size after open radical retropubic prostatectomy. A newly published study reports on the impact of robot-assisted laparoscopic radical prostatectomy (RALP) and penile rehabilitation on penile size.
Filed under: Living with Prostate Cancer, Management, Treatment, Uncategorized | Tagged: length, penile, prostatectomy, RALP, rehabilitation, robot-assisted | Leave a Comment »
KW-2170 is a drug that had been undergoing early clinical trials in Australia for the treatment of men with castration-resistant prostate cancer (CRPC).
Filed under: Drugs in development | Tagged: castration-resistant, CRPC, KW-2170 | Leave a Comment »
A new paper in the Scandinavian Journal of Urology and Nephrology has provided detailed information about the design and conduct of an ongoing, prospective, non-randomized trial comparing open radical retropubic prostatectomy (RRP) to robot-assisted laparoscopic radical prostatectomy (RALP) in treatment of localized prostate cancer.
Filed under: Management, Treatment | Tagged: comparative, effectiveness, localized, open, RALP, robot-assisted, RRP, surgery | Leave a Comment »
According to a report on the Scientific American web site, 87 percent of respondents to a survey conducted by researchers at Tufts Medical Center would be willing to have a hypothetical “predictive” test for prostate cancer.
Filed under: Diagnosis, Risk | Tagged: accurate, hypothetical, test | Leave a Comment »
A new paper just published online in Urology suggests that intermittent and testosterone (T)-based LHRH regimens are less likely to be associated with early onset of castration resistance than traditional, continuous, calender-based regimens.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, agonist, androgen deprivation, castration-resistance, LHRH, monotherapy, regimen | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site